Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

cipaglucosidase alfa-atga (Pombiliti)

cipaglucosidase alfa-atga is an FDA-licensed reference biologic from Amicus Therapeutics US, LLC.

351(a) biologicBLA 761204 Amicus Therapeutics US, LLC
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2023

Reference product

Originator biologic
351(a)BLA 761204

Pombiliti cipaglucosidase alfa-atga

Amicus Therapeutics US, LLC

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for cipaglucosidase alfa-atga from the RCSB Protein Data Bank (PDB 5KZW).

3D molecular structure of cipaglucosidase alfa-atga (PDB entry 5KZW)

Interactive biological assembly from PDB entry 5KZW. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference cipaglucosidase alfa-atga product.

    3 yr ago

cipaglucosidase alfa-atga: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for cipaglucosidase alfa-atga.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.